BMS-5

SKU: orb1222745

Description

LIMKI-3, also known as BMS-3, is a Potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.

Key Properties

• CAS Number: 1338247-35-0
• MW: 431.29
• Purity: >98% (HPLC)
• Formula: C₁₇H₁₄Cl₂F₂N₄OS
• SMILES: O=C(Nc1ncc(s1)c2cc(nn2c3c(Cl)cccc3Cl)C(F)F)C(C)C
• Target: PDGFR
• Solubility: DMSO : ≥ 34 mg/mL; 78.83 mM

Bioactivity

• In Vivo:
  BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01).
  Read more...
• In Vitro:
  BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2ΔEx2 mouse Schwann cells (MSCs) with an IC50 of ~2 μM. BMS-5 (LIMKi 3) reduces Nf2ΔEx2 MSC viability in a dose-dependent manner with an IC50 of 3.9 μM, but does not significantly reduce the viability of control Nf2flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 μM BMS-5, Nf2ΔEx2 MSC viability is 40% compared to 83% for controls.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LIMKI-3 | LIMKI 3 | LIMKI3 | BMS-5

Quick Database Links

Gene Symbol

PDGFR